Quick answers for midlife on a GLP-1
Four things to know before the detail.
- Perimenopause is not a listed use. No GLP-1 label names perimenopause or menopause as an approved use.
- Symptoms can overlap. Tiredness, poor sleep and mood swings can come from midlife changes, the medicine or everyday life. Logging when each one shows up is a clear way to start sorting them.
- Birth control still counts. Pregnancy is still possible until menopause is confirmed, and several GLP-1 labels have specific notes on birth control pills and pregnancy planning.
- Months tell more than days. Perimenopause can last for years, and change on a GLP-1 is gradual. Trends over months give a fairer picture than any single bad week.
Is a GLP-1 approved for perimenopause?
No. This is what each current label lists. The weight-reduction and blood-sugar uses are approved alongside diet and physical activity, and none of the uses mentions perimenopause, menopause or menopause symptoms.
| Medicine | Ingredient and form | Approved uses on the label | Boxed warning | Label revised |
|---|---|---|---|---|
| Wegovy® | Semaglutide, weekly injection or daily tablet | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition (the injection also in children 12 and older with obesity); lowering the risk of major heart events in adults with heart disease and obesity or overweight; the injection also for a type of fatty liver disease (MASH) with liver scarring in adults | Risk of thyroid C-cell tumors | 06/2026 |
| Zepbound® | Tirzepatide, weekly injection | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity | Risk of thyroid C-cell tumors | 08/2026 |
| Mounjaro® | Tirzepatide, weekly injection | Blood sugar control in type 2 diabetes (adults and children 10 and older); lowering the risk of major heart events in adults with type 2 diabetes at high risk | Risk of thyroid C-cell tumors | 08/2026 |
| Ozempic® | Semaglutide, weekly injection | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease; lowering the risk of kidney decline, kidney failure and heart-related death in adults with type 2 diabetes and chronic kidney disease | Risk of thyroid C-cell tumors | 05/2026 |
| Rybelsus® and Ozempic® tablets | Semaglutide, daily tablet | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes at high risk | Risk of thyroid C-cell tumors | 01/2026 |
| Foundayo™ | Orforglipron, daily tablet | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition | Risk of thyroid C-cell tumors | 07/2026 |
What do the weight labels cover?
Wegovy®, Zepbound® and Foundayo™ are approved, with a reduced-calorie diet and more activity, to reduce excess body weight in adults with obesity, or overweight plus at least one weight-related condition. None of these labels mentions perimenopause or menopause.
What do the diabetes labels cover?
Mounjaro®, Ozempic® and Rybelsus® are approved to improve blood sugar control in type 2 diabetes, with heart-related (and, for Ozempic®, kidney-related) approvals for certain adults with type 2 diabetes. They are not approved for weight loss or for midlife symptoms.
What have studies looked at in midlife?
The trials behind the weight labels enrolled many women but were not designed to look at menopause status. Most of what is known about midlife women comes from later analyses and clinic records, including small observational studies of women who also used hormone therapy. Observational studies cannot show cause and effect.
Our guide to menopause weight gain and GLP-1 medications walks through those studies, what the SWAN study found about body composition in the transition, and bone health.
Is midlife weight change a prescriber conversation?
Yes. Weight often shifts during perimenopause, and the reasons differ from person to person. Your prescriber can tell you whether any medicine is a fit and which approved use would apply.
What about hormone therapy and other pills?
The labels note that slower stomach emptying may affect how other medicines taken by mouth are absorbed. Give your prescriber a full list of everything you take, including hormone therapy, birth control and supplements.
What is the boxed warning on these labels?
Every label on this page opens with a boxed warning, the FDA's most prominent kind, about the risk of thyroid C-cell tumors. GLP-1 medicines caused these tumors in rats and mice, and it is not known whether they cause them in people, including a thyroid cancer called medullary thyroid carcinoma (MTC). The Foundayo™ label notes that orforglipron is not active in rodents and did not cause tumors in them, and it carries the same boxed warning.
All six labels say not to use the medicine if you or a family member has had MTC, or if you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The Medication Guides tell patients to contact their healthcare provider about a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.
Midlife changes or side effects? Sorting out the overlap
This is the core problem in midlife. Timing will not give you a diagnosis, but it gives you and your prescriber something better than a guess.
Fatigue shows up on both lists
Fatigue is in the weight-trial side-effect tables on the Wegovy®, Zepbound® and Foundayo™ labels; the Ozempic® label also lists fatigue among less common reactions, and the Mounjaro® label reports it in its heart-outcomes trial. It is also common in perimenopause. Noting when it starts and how strong it feels is more useful than guessing the cause.
Timing is the clue
The Zepbound® label says most nausea, vomiting and diarrhea happened while the dose was being increased and became less common over time. Symptoms that follow your shot days or dose increases point one way, while symptoms that follow your cycle point another.
What the labels do not list
Hot flashes, flushing, night sweats and period changes are not listed as side effects on these labels. The guide to period changes, hot flashes and fatigue on a GLP-1 explains how to log them if they change.
When to call instead of wait
Severe stomach pain that will not go away, signs of dehydration or signs of an allergic reaction need prompt care. For anything new that worries you, call your prescriber rather than waiting for a pattern.
Birth control still matters before menopause
Many people assume pregnancy is no longer possible in their forties. Until menopause is confirmed, it can still happen, even when periods are irregular. Ask your prescriber how long birth control is still needed for you.
The pill and tirzepatide (Mounjaro®, Zepbound®)
The Mounjaro® and Zepbound® labels say tirzepatide may reduce how well birth control pills work, because it slows stomach emptying, and that this delay is largest after the first dose and lessens over time. They advise people using oral hormonal birth control to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Hormonal birth control that is not taken by mouth should not be affected, the labels say.
Birth control and Foundayo™
The Foundayo™ label asks women who could become pregnant to use effective birth control during treatment. Because slower stomach emptying may affect how pills are absorbed, it advises people using oral hormonal birth control to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase.
Semaglutide and pregnancy planning (Wegovy®, Ozempic®, Rybelsus®)
The Wegovy®, Ozempic®, and Rybelsus® and Ozempic® tablets labels say to stop the medicine at least 2 months before a planned pregnancy, because semaglutide stays in the body a long time. The tirzepatide and Foundayo™ labels do not set a similar stopping window, so ask your prescriber about timing well ahead of any plans.
If a pregnancy happens
The Wegovy®, Zepbound® and Foundayo™ labels say weight loss offers no benefit during pregnancy and may cause harm to the baby. Zepbound® and Foundayo™ say to stop once a pregnancy is recognized, and Wegovy® says to stop it in pregnant patients using it for weight reduction or heart-risk reduction. The Mounjaro®, Ozempic®, and Rybelsus® and Ozempic® tablets labels, written for type 2 diabetes, say the medicine should be used in pregnancy only if the potential benefit justifies the potential risk to the baby. Whichever you take, contact your prescriber right away.
From the makers of this guide
What to log over the months ahead
A short, realistic list you can keep up for months. Each item is something Pep AI records today.
- 01
Sleep and night waking
The daily check-in asks how you slept, alongside energy and mood. Sleep hours can sync from Apple Health on iPhone or Health Connect on Android. A few weeks of check-ins can help show whether bad nights cluster around shot days or follow a different rhythm.
- 02
Symptoms you name yourself
Choose from a built-in list that includes fatigue, insomnia, mood changes, night sweats and joint pain (turn on the ones you want under What to Track), or add your own, such as hot flashes. Each is rated and dated, and you can add a note for the day.
- 03
Shot days without the mental load
Shot-day reminders keep a busy stretch on track, and each medicine can have its own schedule. On iPhone (iOS 17 and later), one-tap logging from the Lock Screen Live Activity and the large home screen widget, and dose logging on the Apple Watch app, help too.
- 04
Compare symptoms with your dose dates
Your dose history, symptom log, check-ins and weight are all dated, so you can compare when a symptom showed up with your shot days and dose increases.
Questions worth asking at your next visit
A short list of questions keeps decisions with your prescriber, and gives you a reason to keep a log.
- Which changes should I watch? Ask which symptoms your prescriber wants to hear about right away and which can wait.
- How does this fit with hormone therapy? If you use or are considering hormone therapy, ask how the two fit together. Your prescriber or menopause specialist decides what is right for you.
- Do I still need birth control? Ask how long it is needed, and whether your current method works with your medicine. The tirzepatide and Foundayo™ labels have specific notes on birth control pills.
- What does progress look like for me? Progress in midlife may not be a straight line on the scale. Ask what to watch besides weight, such as energy, sleep and strength.
Key takeaways
- No GLP-1 medication is FDA-approved for perimenopause, menopause or their symptoms; none of the labels lists them.
- Fatigue is on the Wegovy®, Zepbound® and Foundayo™ labels, and the Ozempic® and Mounjaro® labels list it too; it is also common in perimenopause, while hot flashes and period changes are not on the labels.
- Timing helps: symptoms that follow shot days or dose increases point one way, and symptoms that follow your cycle point another.
- Pregnancy is possible until menopause is confirmed. Mounjaro®, Zepbound® and Foundayo™ have birth control pill notes, and the semaglutide labels say to stop at least 2 months before a planned pregnancy.
- Every label carries a boxed warning about thyroid C-cell tumors. Decisions about hormone therapy and GLP-1s belong with your prescriber.
Sort the overlap with a record, not a guess.
Pep AI logs your doses, symptoms, sleep, mood and weight, and makes a PDF of your doses and weight for your prescriber. Free to try on iPhone and Android.
Frequently asked questions
Keep reading
Sources
- Wegovy® (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Mounjaro® (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
- Ozempic® (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk / FDA (revised 05/2026)
- Rybelsus® and Ozempic® tablets (semaglutide) prescribing information, Novo Nordisk / FDA (revised 01/2026)
- Foundayo™ (orforglipron) prescribing information, Eli Lilly / FDA (revised 07/2026)
This guide is general information based on FDA prescribing information and published research. No GLP-1 medication is FDA-approved for perimenopause, menopause or their symptoms. Decisions about hormone therapy and GLP-1 medicines belong with your clinician. Pep AI does not recommend any medicine, any dose, or any use that is not on a medicine's label. It is not medical advice and does not replace your prescriber, gynecologist or pharmacist, and Pep AI is not affiliated with Novo Nordisk or Eli Lilly. If a symptom is severe, getting worse, or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026